NCT04730206

The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

The DAWN Antivirals Trial: the Efficacy of Antivirals for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: KU Leuven · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.

Detailed description

In patients aged 40 years and above and diagnosed with Covid-19 upon study entry, we will evaluate the efficacy of camostat or molnupiravir on recovery within 30 days after randomisation. Participants will be randomly assigned to camostat, molnupiravir or placebo using a computer generated randomisation process. Participants will be treated for 7 days in case of camostat and 5 days in case of molnupiravir, and follow-up will be 30 days.

Conditions

• Covid19
• SARS-CoV Infection

Interventions

Type	Name	Description
DRUG	Camostat	100 milligram tablets
DRUG	Placebo	oral tablets, identical in size and shape
DRUG	Molnupiravir	200 milligram tablets

Timeline

• Start date: 2021-06-15
• Primary completion: 2022-07-13
• Completion: 2022-07-13
• First posted: 2021-01-29
• Last updated: 2022-10-03

Locations

1 site across 1 country: Belgium